# STAT News

Type: Company

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/stat-news-company
Canonical HTML page: https://getbiobrief.com/entity/stat-news-company

## Timeline

- **2026-08-19T20:15:00Z**: Hartford Courant reports Trump picks Overton — The Hartford Courant reports Trump picks Dr. Heidi Overton, a top White House aide, to lead the FDA.
- **2026-08-19T20:00:00Z**: ABC7 News reports Trump picks Overton — ABC7 News publishes a headline stating Trump picks Dr. Heidi Overton, a top White House aide, to lead the FDA.
- **2026-08-19T01:18:25Z**: STAT News reports Trump expected to pick Overton — STAT reports that President Trump is expected to choose White House adviser and physician Heidi Overton to lead the Food and Drug Administration.
- **2026-03-10**: STAT Analysis Released — Data confirms a 35% nosedive in Big Pharma antimicrobial R&D over the preceding 60 months.
- **2025-11-20**: Small Biotech Crisis — A wave of bankruptcies among small antibiotic developers highlights the 'broken market' for new treatments.
- **2023-06-15**: Market Exit Acceleration — Several large pharma entities announce the closure of infectious disease units to focus on chronic therapies.
- **2021-03-10**: Baseline Period — Major drugmakers maintain active antimicrobial pipelines before a steady five-year decline begins.

## Recent coverage (2 stories)

### Overton FDA pick: 3 drug approval questions biotech must watch
2026-08-19 21:11:52 · Sentiment: Neutral · Impact: 7/10 · Sources: 3

Biotech and pharma investors and executives face a potentially new FDA commissioner with no public drug-review track record. If Dr. Heidi Overton is confirmed, her priorities could reshape clinical trial standards, accelerated approval pathways, and review timelines. Early signals from the White House and confirmation hearings will matter most.
Full story: https://getbiobrief.com/story/overton-fda-biotech-approval-questions

### Big Pharma’s Antibiotic Pipeline Shrinks 35% as Market Failures Deepen
2026-03-10 11:45:16 · Sentiment: Negative · Impact: 7/10 · Sources: 2

A new analysis reveals a 35% decline in antimicrobial R&D by major pharmaceutical companies over the last five years, highlighting a deepening crisis in the fight against drug-resistant superbugs. The exodus of large-scale investment underscores the persistent lack of economic incentives for developing life-saving antibiotics.
Full story: https://getbiobrief.com/story/big-pharma-antibiotic-pipeline-decline-analysis

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.